Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

European Journal of Clinical Pharmacology

Volumn 54, Issue 5, 1998, Pages 443-447

  Jorga, K M ^a   Fotteler, B ^a   Heizmann, P ^a   Zurcher G ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

COMT inhibition; Parkinson's disease; Tolcapone

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; TOLCAPONE;

ABDOMINAL DISCOMFORT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; ERYTHROCYTE; FATIGUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; TREMOR;

EID: 0031855536     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050490     Document Type: Article

References (21)

1. Da Prada M, Zürcher G, Napolitano A (1995) Tolcapone (TO) inhibits both peripheral and central catechol-O-methyltransferase (COMT). Neurology 45: A252-A263
2. Zürcher G, Dingemanse J, Da Prada M (1991) Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G (eds) New developments in therapy of Parkinson's disease John Libbey, Rome, pp 37-43
3. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329: 1021-1027
4. Fahn S (1989) Adverse effects of levodopa in Parkinson's disease. In: Calne DB (ed) Drugs for the treatment of Parkinson's disease. Springer, Berlin, Heidelberg New York pp 385-409
5. LeWitt PA (1992) Treatment strategies for extension of levodopa effect. Neurol Clin 10: 511-526
6. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, van Brummelen P (1995) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40: 253-262
7. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, van Brummelen P (1996) Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 50: 47-55
8. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S (1997) Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49: 665-671
9. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S (1997) Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49: 1066-1071
10. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G, on behalf of the study investigators (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63: 421-428
11. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P (1995) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57: 508-517
12. Timm U, Erdin R (1992) Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 593: 63-68
13. Nohta H, Noma S, Onkura Y, Yoo BT (1984) Assay for catechol-O-methyltransferase in erythrocytes using a new fluorogenic substrate, 2-(3,4-dihydroxyphenyl)naphtho[1,2-d]-thiazole. J Chromatogr 308: 93-100
14. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
15. Holford NHG, Sheiner LB (1981) Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 5: 273-322
16. Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35-49
17. Keränen T, Gordin A, Karlson M, Korpela K, Pentikäinen PJ, Rita H, Schultz E, Seppälä L. Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151-157
18. Männistö PT, Tuomainen P, Tuominen RK (1992) Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 105: 569-574
19. Keränen T, Gordin A, Harjola VP, Karlson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145-156
20. Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G, Aitken J (1997) The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa benserazide formulations. Eur Neurol 38: 59-67
21. Boomsma F, Meerwalot JD, Man in t Veld AJ, Hovestadt A, Schalekamp MADH (1989) Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Ann Neurol 25: 624-628